





(51) International Patent Classification:
C07C 50/18 (2006.01) C07C 225/34 (2006.01)(21) International Application Number:
PCT/US2012/063746(22) International Filing Date:
6 November 2012 (06.11.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/556,245 6 November 2011 (06.11.2011) US(71) Applicant: BETA CAT PHARMACEUTICALS, LLC
[US/US]; 22 Firstfield Road, Suite 280, Gaithersburg, MD
20878 (US).(72) Inventors: BHALLA, Kapil, N.; 22 Firstfield Road, Suite
280, Gaithersburg, MD 20878 (US). HERRIGAN, Stephen;
22 Firstfield Road, Suite 280, Gaithersburg, MD 20878
(US).(74) Agents: POLYAKOV, Mark, V. et al.; Wood, Phillips,
Katz, Clark & Mortimer, 500 West Madison Street, Suite
1130, Chicago, IL 60661 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β -LIKE PROTEIN
1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA(57) Abstract: The present invention discloses utilization of the anthracene-9,10-di-
one dioxime compound: 2-((3R,5S)-3,5-dimethylpiperidin-1-ylsulfonyl)-7-((3S,5R)-
3,5-dimethylpiperidin-1-ylsulfonyl)anthracene-9,10-dione dioxime for the treat-
ment of cancer, including myeloproliferative neoplasia, chronic myeloid leukemia and acute
myeloid leukemia. Such an anthracene- 9,10-dione dioxime compound interrupts the
Wnt/beta-catenin pathway and inhibits the deregulated activity of this pathway for the
treatment, diagnosis and prevention of beta-catenin pathway-related disorders, as well
as disrupting transducin beta-like protein 1 (TBL1) interaction with the coactivator
molecule beta-catenin.



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, **Published:**

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*